Previous 10 | Next 10 |
– Novel HBV-neutralizing monoclonal antibody with therapeutic vaccine potential demonstrated a mean HBsAg reduction from baseline of 1.3 log10 IU/mL by day eight – SAN FRANCISCO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced initia...
H.C. Wainwright raises Vir's (VIR) price target from $100 to $125Analyst Patrick Trucchio writes that the company's COVID-19 antibody treatment, VIR-7831, could account for $80, up from a prior estimate of $55.Wainwright says VIR-7831, which is in Phase 3, has an 85% chance of success.Trucchi...
H.C. Wainwright raises Vir Biotech's (VIR) price target from $100 to $125, suggesting a more than triple from last night's close of $39.Analyst Patrick Trucchio writes that the company's COVID-19 antibody treatment, VIR-7831, could account for $80 in share value, up from a prior estimate of $...
The following slide deck was published by Vir Biotechnology, Inc. in conjunction with this event. For further details see: Vir Biotechnology (VIR) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
Thought to be highly promising when they received the regulatory nod, the monoclonal antibody therapies against COVID-19 appear to have failed to deliver their maximum potential.Due to difficulties in administration, logistical issues, etc., they remain underutilized in the healthcare...
Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK) . Partnership...
Gilead Sciences (GILD) and Vir Biotechnology (VIR) announces that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus ((HBV)).The companies plan to initiate a Pha...
-- First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research -- Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collabora...
Vir Biotechnology (VIR) and GlaxoSmithKline (GSK) announce an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. The AGILE trial platform will be the first to test VIR-7832 in humans for COVID-19, the...
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...